BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 36290850)

  • 1. Current Clinical Practice of Precision Medicine Using Comprehensive Genomic Profiling Tests in Biliary Tract Cancer in Japan.
    Kanai M
    Curr Oncol; 2022 Sep; 29(10):7272-7284. PubMed ID: 36290850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Status of Next-Generation Sequencing-Based Cancer Genome Profiling Tests in Japan and Prospects for Liquid Biopsy.
    Yoshii Y; Okazaki S; Takeda M
    Life (Basel); 2021 Aug; 11(8):. PubMed ID: 34440540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Additional Remarks on the Issue of Cancer Genomic Medicine-Focusing on Medical Insurance Issues].
    Nishihara H
    Gan To Kagaku Ryoho; 2022 Sep; 49(9):1011-1013. PubMed ID: 36156029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities.
    Matsubara J; Mukai K; Kondo T; Yoshioka M; Kage H; Oda K; Kudo R; Ikeda S; Ebi H; Muro K; Hayashi R; Tokudome N; Yamamoto N; Muto M
    JAMA Netw Open; 2023 Jul; 6(7):e2323336. PubMed ID: 37459099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Budget impact analysis of comprehensive genomic profiling for untreated advanced or recurrent solid cancers in Japan.
    Tang W; Hanada K; Motoo Y; Sakamaki H; Oda T; Furuta K; Abutani H; Ito S; Tsutani K
    J Med Econ; 2023; 26(1):614-626. PubMed ID: 37073487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study.
    Garcia-Pardo M; Ortega L; Fernández-Aceñero MJ; García Alfonso P; Martín M; Muñoz AJ
    J Gastrointest Cancer; 2021 Jun; 52(2):814-818. PubMed ID: 33683644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
    Ross JS; Sokol ES; Moch H; Mileshkin L; Baciarello G; Losa F; Beringer A; Thomas M; Elvin JA; Ngo N; Jin DX; Krämer A
    Oncologist; 2021 Mar; 26(3):e394-e402. PubMed ID: 33219618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC.
    Mack PC; Keller-Evans RB; Li G; Lofgren KT; Schrock AB; Trabucco SE; Allen JM; Tolba K; Oxnard GR; Huang RSP
    Oncologist; 2024 Feb; ():. PubMed ID: 38401173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer.
    Berchuck JE; Facchinetti F; DiToro DF; Baiev I; Majeed U; Reyes S; Chen C; Zhang K; Sharman R; Uson Junior PLS; Maurer J; Shroff RT; Pritchard CC; Wu MJ; Catenacci DVT; Javle M; Friboulet L; Hollebecque A; Bardeesy N; Zhu AX; Lennerz JK; Tan B; Borad M; Parikh AR; Kiedrowski LA; Kelley RK; Mody K; Juric D; Goyal L
    Ann Oncol; 2022 Dec; 33(12):1269-1283. PubMed ID: 36089135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective.
    Reitsma M; Fox J; Borre PV; Cavanaugh M; Chudnovsky Y; Erlich RL; Gribbin TE; Anhorn R
    J Manag Care Spec Pharm; 2019 May; 25(5):601-611. PubMed ID: 30632889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Precision Medicine of Hepatobiliary and Pancreatic Cancers: Focusing on Clinical Trial Outcomes.
    Tsumura T; Doi K; Marusawa H
    Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of comprehensive cancer genomic profiling on therapeutic strategies and clinical outcomes in patients with advanced biliary tract cancer: A prospective multicenter study.
    Takada K; Kubo T; Kikuchi J; Yoshida M; Murota A; Arihara Y; Nakamura H; Nagashima H; Tanabe H; Sugita S; Tanaka Y; Miura A; Ohhara Y; Ishiguro A; Yokouchi H; Kawamoto Y; Mizukami Y; Ohnishi H; Kinoshita I; Sakurai A
    Front Oncol; 2022; 12():988527. PubMed ID: 36119486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Druggable gene alterations in Japanese patients with rare malignancy.
    Ohmoto A; Hayashi N; Fukada I; Yamazaki M; Yunokawa M; Kasuga A; Shinozaki E; Ueki A; Tonooka A; Takeuchi K; Mori S; Kiyotani K; Takahashi S
    Neoplasia; 2022 Nov; 33():100834. PubMed ID: 36088851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers.
    Boilève A; Verlingue L; Hollebecque A; Boige V; Ducreux M; Malka D
    Expert Opin Investig Drugs; 2021 Apr; 30(4):401-409. PubMed ID: 33641556
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical Significance of Multi-Cancer Genome Profiling: Data from a Single Hospital in Japan.
    Aoyama R; Nishikubo H; Kawabata K; Kanei S; Yamamoto Y; Nishimura S; Yashiro M
    Cancer Genomics Proteomics; 2024; 21(1):79-87. PubMed ID: 38151295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endoscopic ultrasound-guided tissue acquisition for comprehensive genomic profiling.
    Okuno N; Hara K
    J Med Ultrason (2001); 2024 Apr; 51(2):253-260. PubMed ID: 38281237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic profiling and precision medicine in complex ameloblastoma.
    Gates JC; Clark AP; Cherkas E; Shreenivas AV; Kraus D; Danzinger N; Huang RSP; Johnson J; Ross JS
    Head Neck; 2023 Apr; 45(4):816-826. PubMed ID: 36645099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use.
    Proudman D; DeVito NC; Belinson S; Allo MA; Morris ED; Signorovitch J; Patel AK
    J Med Econ; 2022; 25(1):817-825. PubMed ID: 35593483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
    Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
    Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice.
    Jain A; Kwong LN; Javle M
    Curr Treat Options Oncol; 2016 Nov; 17(11):58. PubMed ID: 27658789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.